KENNEDY SPACE CENTER (FL), August 12, 2019 – The International Space Station (ISS) U.S. National Laboratory is embarking upon a multi-year research alliance with the McGowan Institute for Regenerative Medicine (MIRM) at the University of Pittsburgh (Pitt) to push the limits of biomedical research and development aboard the orbiting laboratory.
This alliance — a core element of the ISS National Laboratory Industrial Biomedicine Program — was unveiled at the 8th annual ISS Research and Development Conference held in Atlanta earlier this month. This new partnership will serve as a benchmark for how the ISS National Laboratory develops similar programs in the future involving research and development activities aboard the space station.
The ISS National Laboratory and MIRM will collaborate with partners from industry, other academic research centers, and government agencies to drive the progress of regenerative medicine research onboard the ISS. As part of this alliance, Pitt will develop Earth-based facilities on campus to advance research and meet with potential partners, while working in coordination with the ISS National Laboratory on flight opportunities to the orbiting laboratory. The program will focus on microgravity life sciences research and development, with a line of sight toward products and services for clinical application on Earth.
For instance, exploiting the unique behavior of stem cells in microgravity could improve cell-based therapies for a variety of diseases and impairments, such as traumatic brain injury and type I diabetes. Similarly, microgravity could allow 3D printers to create complex tissue structures that are difficult to achieve in the presence of full gravity.
“As the premier partner for the Industrial Biomedicine Alliance with the ISS National Laboratory, we look forward to using the space station as a testbed for regenerative medicine advances and product development in low Earth orbit,” said MIRM Director William R. Wagner, Ph.D.
“The McGowan Institute has built on its deep history advancing the development of artificial organs to establish a position of internationally recognized leadership in regenerative medicine,”said Rob A. Rutenbar, Ph.D., senior vice chancellor for research at Pitt. “The ISS National Laboratory will benefit from that deep expertise, as well as our commitment to rapid clinical translation.”
The products of the Industrial Biomedicine Program and this research partnership will help build the fundamental business case for the industrialization of crewed platforms in low Earth orbit. In future alliances, the ISS National Laboratory will work with companies and research partners who seek to better understand and find solutions to common problems on Earth through space-based experimentation on the ISS National Laboratory.
“The ISS National Laboratory is proud to announce this alliance with Pitt and MIRM in order to develop biomedical products in space that could benefit human health on Earth,” said ISS National Laboratory Chief Strategy Officer Richard Leach, Ph.D. “Part of the role of the ISS National Laboratory is to create and implement innovative strategies to enhance the research capacity of the orbiting laboratory, and we believe alliances like this will pave the way for future collaborations to advance the discoveries of space-based science.”
To learn more about innovative research taking place aboard the ISS National Laboratory, visit www.ISSNationalLab.org.
Erin Hare (MIRM)
# # #
About the International Space Station (ISS) U.S. National Laboratory: In 2005, Congress designated the U.S. portion of the ISS as the nation’s newest national laboratory to optimize its use for improving quality of life on Earth, promoting collaboration among diverse users, and advancing science, technology, engineering, and mathematics (STEM) education. This unique laboratory environment is available for use by non-NASA U.S. government agencies, academic institutions, and the private sector. The ISS National Laboratory manages access to the permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space.
About the McGowan Institute for Regenerative Medicine: The University of Pittsburgh School of Medicine and UPMC established the McGowan Institute for Regenerative Medicine in 2001. The McGowan Institute serves as a single base of operations for the university’s leading engineers, scientists and clinical faculty working in the areas of tissue engineering, cellular therapies, and medical devices. The Institute’s mission includes the development of innovative clinical protocols, as well as the pursuit of rapid commercial transfer of its technologies related to regenerative medicine. There are more than 250 McGowan-affiliated faculty who have collectively filed over 1,600 patents worldwide, licensed or optioned 185 patents with outside partners and produced more than 30 spinout companies. For more information, visit www.mirm.pitt.edu.
About the University of Pittsburgh: A nonsectarian, coeducational, state-related, public research university founded in 1787, the University of Pittsburgh (Pitt) is a member of the prestigious by-invitation-only Association of American Universities and internationally renowned as a leading center of learning and research in the arts, sciences, humanities, professions, and health sciences. Comprising a Pittsburgh campus, which is home to 16 undergraduate, graduate, and professional schools, and four Western Pennsylvania regional campuses, Pitt offers nearly 500 distinct degree programs and confers more than 8,500 degrees annually. Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998 and is ranked among the top 10 American research universities nationally in terms of total federal science and engineering research and development obligations. For more information, visit www.pitt.edu.